Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index
Christine Desmedt, Marco Fornili, Florian Clatot, Romano Demicheli, Davide De Bortoli, Angelo Di Leo, Giuseppe Viale, Evandro de Azambuja, John Crown, Prudence A Francis, Christos Sotiriou, Martine Piccart, Elia Biganzoli
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
PURPOSE: Lipophilic drugs, such as taxanes, have a high affinity for adipose tissue and a resulting higher volume of distribution. Here, we reanalyzed clinical trial data to investigate whether the efficacy of docetaxel-based chemotherapy differs from non-docetaxel-based chemotherapy in patients with breast cancer according to their baseline body mass index (BMI). PATIENTS AND METHODS: We retrospectively analyzed data from all of the patients in the adjuvant BIG 2-98 trial (ClinicalTrials.gov identifier: NCT00174655; N = 2,887) comparing non-docetaxel- to docetaxel-containing chemotherapy. BMI (kg/m2) was categorized as follows: 18.5 to < 25, lean; 25 to < 30, overweight; and ≥ 30, obese. Di..View full abstract
Supported in part by Fondation Cancer Luxemburg (to C.D.) and Associazione Italiana per la Ricerca sul Cancro AIRC (to E.B.).